Psychedelic research sheds light on experiences such as empathy and unity that cross cultural boundaries and speak to shared human qualities.| The Debrief
San Jose, CA; September 4, 2025 — In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder (PTSD). Today, the FDA made this CRL publicly available for the first time, providing transparency into the agency’s decision-making process. … Continue reading MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy| Multidisciplinary Association for Psychedelic Studies – MAPS
WASHINGTON, DC (August 14, 2025) — One year after the FDA’s denial of the New Drug Application for MDMA-assisted therapy for PTSD, the Multidisciplinary Association for Psychedelic Studies (MAPS) has issued an open letter to the U.S. Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr., and Dr. Martin A. Makary, the Commissioner… Continue reading MAPS Urges Action: Open Letter to HHS Secretary and FDA Commissioner One Year After FDA Denial of MDMA-Assisted Therapy for PTSD| Multidisciplinary Association for Psychedelic Studies – MAPS
From DMT vapes to MDMA gummies, psilocybin mushroom chocolate bars, and LSD microdots, an expanding range of psychedelic Consumer Packaged Goods (CPG) products is becoming increasingly available in the U.S. and Europe. The post The Booming Market For Psychedelic Consumer Packaged Goods first appeared on Lucid News. The post The Booming Market For Psychedelic Consumer Packaged Goods appeared first on Lucid News.| Lucid News
Voor XTC (MDMA) bestaat er geen veilige dosis. Sommige mensen zijn zo gevoelig voor de bijwerkingen van XTC dat bij hen al […] The post Is 1 mg MDMA per kg lichaamsgewicht een veilige dosis? appeared first on Drugs en Uitgaan.| Drugs en Uitgaan
The Department of Defense just gave the University of Texas a $4.9M grant to study MDMA to treat PTSD in veterans groups.| HealingMaps
Therapist Charles Wininger offers an elder's perspective on how to approach the election and its aftermath from a psychedelic point of view.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
In the first part of a two-part series, Ann Harrison interviews addiction treatment expert Dr. Howard Kornfeld about the FDA decision to reject the Lykos Therapeutics proposal for MDMA-assisted therapy.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
In the wake of the FDA's rejection of its proposed MDMA-assisted therapy for PTSD, Lykos Therapeutics laid off approximately 100 employees and appointed new leadership while the MAPS nonprofit cut 33% of its workforce.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
Prior to last week's FDA decision to reject Lykos Therapeutics' proposed MDMA-assisted therapy for PTSD, Rep. Jack Bergman (R-MI) reflected on the urgent need for better PTSD treatments to reduce veteran suicides and the game plan for lawmakers to keep support for psychedelic-assisted therapies moving forward.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
FDA taps the brakes on MDMA therapy approval, requesting additional evidence to ensure safety and efficacy for PTSD treatment.| Synergetic Press
The FDA has rejected Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD and requested an additional Phase 3 study.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics awaits an FDA decision this week on its proposed MDMA-assisted therapy for PTSD, the company has announced new initiatives and measures for additional oversight if the therapy is approved.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
A Conversation with Sam Harris - Deconstructing Yourself| Deconstructing Yourself
Peyton Nyquvest is the CEO of Numinus, a Canadian publicly-traded company that is involved in psychedelic synthesis, research and treatment. Numinous recently partnered with MAPS Public Benefit Corporation to host […] The post Psychedelic Treatment in Canada: Interview with Payton Nyquvest of Numinus appeared first on Psychedelic Times.| Psychedelic Times
In 2018, I changed my mind about drugs. Like many, I am getting more stuck in my ways as I age. I’m still in my 30s, but compared to a decade ago, I change my mind less often, I do more things by routine, and I take more things as settled fact. I am less [...]Read More...| RyanWaggoner.com